SNDX vs. MLTX, IMVT, AAPG, CRNX, KYMR, MOR, HCM, RARE, ALVO, and AMRX
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), Ascentage Pharma Group International (AAPG), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.
Syndax Pharmaceuticals vs. Its Competitors
Syndax Pharmaceuticals (NASDAQ:SNDX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Syndax Pharmaceuticals presently has a consensus price target of $34.10, indicating a potential upside of 241.34%. MoonLake Immunotherapeutics has a consensus price target of $74.50, indicating a potential upside of 35.38%. Given Syndax Pharmaceuticals' higher probable upside, equities research analysts clearly believe Syndax Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -757.53%. MoonLake Immunotherapeutics' return on equity of -30.81% beat Syndax Pharmaceuticals' return on equity.
93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Syndax Pharmaceuticals had 8 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 1 mentions for MoonLake Immunotherapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.36 beat MoonLake Immunotherapeutics' score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Syndax Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Summary
MoonLake Immunotherapeutics beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SNDX) was last updated on 7/24/2025 by MarketBeat.com Staff
